Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Background Early P2Y 12 inhibitor monotherapy has emerged as a promising alternative to
12 months of dual antiplatelet therapy following percutaneous coronary intervention (PCI) …

Inflammatory bowel disease (IBD) is a pathological condition that first involves the
gastrointestinal wall but can also trigger a systemic inflammatory state and thus …

Objective To estimate the incidence and HRs for bleeding for different dual antiplatelet
therapies (DAPT) in a real-world population with acute coronary syndrome (ACS) …

Background The incidence and predictors of bleeding after acute coronary syndrome are
unclear within the real‐world setting. Our objective was to determine the incidence, types …

Progress in decreasing ischemic complications in acute coronary syndrome (ACS) has
come at the expense of increased bleeding risk. We estimated the long-term, post-discharge …

Abstract Objective The POPular AGE trial showed that clopidogrel significantly reduced
bleeding risk compared with ticagrelor without any signs of an increase in thrombotic events …

Background Early aspirin withdrawal, also known as P2Y 12-inhibitor monotherapy,
following percutaneous coronary intervention (PCI) for non-ST-segment elevation acute …

Objective Patients with acute coronary syndrome (ACS) remain at high risk for recurrent
ischaemic and bleeding events during follow-up. Our study aimed to quantify and compare …

Introduction The increased life expectancy of patients with haemophilia A (HA) has led to a
growing prevalence of cardiovascular risk factors and events. There is still scarce evidence …